New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026
Oncopeptides AB (publ), a biotech firm targeted on difficult-to-treat cancers, at this time proclaims that two abstracts highlighting real-world scientific ...
